Nanoviricides Inc., NNVC on the AMEX , Ranked BUY
NNVC has been verified long ago not to be scam, cheat or fiddle of a company. Scientific reference books have explained and delineated the fundamentals and legitimacy of NNVC therapeutic advancements (ref - CRC publication Bionanotechnology II ISBN -10: 143980463X).
Institutional investors have made review and purchased shares after having demonstrated acceptance to the NYSE/AMEX. (Ref - Vanguard, Goldman Sacks, Deutsche Bank, et.al.)
Working within the pharmaceutical industry protocols to perform in vitro and later, animal testing, prior to human phases, NNVC has been documented to have had excellent success in both. (Ref – H5N1 & Rabies at the National Institute of Hygiene and Epidemiology in Hanoi, Ebola studies with the United States Army Institute of Infectious Diseases, Epidemic Kerato-Conjunctivitis EKC, anti-Herpes clinical study with THEVAC and Herpes Simplex Virus HSV with Dr. Rosenthal at NEOMED, anti-HIV therapeutics testing with the University of California in addition to KARD Scientific, Dengue Fever tests with Dr. Eva Harris at the University of California, Berkeley, et.al)
The majority of all testing has reported excellent efficacy against the viral types targeted, with no apparent toxicity issues. In proceeding with the normal course of new drug development the FDA granted a pre-IND meeting, which upon being held gave guidance for facility and testing requirements to proceed to first human phase testing. After much effort, NNVC is currently finalizing the facility and preparing for such testing. The FDA and the European medical agencies were also impressed enough to grant NNVC’s Denque Fever anti-viral an orphan drug designation.
The Chair Professor of Ophthalmology at Baylor College of Medicine, and a Director of the Company, was asked why he invested a total of $7M ($7,000,000.00 USD) in NNVC during the 2013 calendar year. His answer was, “As I became familiar with the technology and the various on-going programs that the Company has, it became apparent that the potential was nothing short of amazing”.
It is possible that as a director, he could have some bias, but it is the writer’s understanding that he was originally made aware of the company by a family member that impressed by the testing she was doing on one of the company’s anti-viral compounds. The point however, is that this well respected doctor, doctors and institutions in other countries, Dr. Harris, Dr. Rosenthal, as well as others, including financial institutions like Vanguard and Goldman, including the FDA, find NNVC credible and worthy of note and respect due.
It is in the writer’s opinion, that if some person, or group puts forth the suggestion that NNVC is a company built upon a scam or a fraud, or is a ‘snake oil’ stock, that their statements or actions are more apt to be based on deceitful ulterior motives designed to promulgate their own scam or fraud, however large or small, than based on the reality of the company or its technology.
It is the writer’s opinion that from a developmental company standpoint and from an industry comparative and historical perspective, NNVC has shown good stewardship of funding by achieving excellent efficacy results for the total invested dollar value to date.
It would also be naïve of the writer to assume no missteps have been made and/or clear skies lie ahead. Like all companies, NNVC has been presented with its own set of corporate, technical, business and legal issues. Some likely brought about by their own mistakes or imperfect actions while others made by the assortment of those outside with their own agendas, good or bad. So far though, NNVC appears to have managed their funds effectively to be on the doorsteps of human trials of a potential game changing anti-viral therapeutic product. For that they should be commended.
It is important for all investors to do their own due diligence. It is best to avoid tendencies blindly follow or blindly assume accuracy and legitimacy of positive or negative commentary. It is also critical to understand one’s risk level and beware of misinformation. Recognize that not all misinformation is intentional, while other cases are indeed malicious and/or manipulative in nature.
The writer currently maintains a small equity position in NNVC common stock and as such could be suspected of bias. While not in the medical or pharmaceutical field, a background in science and engineering, including chemical process R&D experience, has been of immense help to the writer in recognizing true technical merit in areas investigated over the last 30+ years. It is a humble opinion that NNVC has a valuable new therapeutic platform and would be a loss to humanity if it were to ultimately be unsuccessful.
It is also a humble opinion that NNVC, like many others, will have headwinds by the relentless capability of the business and investing world to put forth a nearly endless list of obstacles to almost any endeavor, regardless of the underlying technology, worth, or legitimacy.
All said and considered, it is the writer’s opinion NNVC is BUY in the speculative biotech equity category.
